Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
Zanubrutinib plus obinutuzumab for treating relapsed or refractory follicular lymphoma Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Zanubrutinib (BGB-3111; Brukinsa) Follicular lymphoma Haematological Cancer and Lymphomas 2023 View  |  Download
Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis Mycophenolate mofetil (Cellcept) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) Lupus nephritis Immunology , Nephrology 2023 View  |  Download
Ibrutinib with Venetoclax and Obinutuzumab for the treatment of Chronic Lymphocytic Leukaemia patients with TP53 deletion and/or mutation Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma in elderly – first line Ibrutinib (Imbruvica) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2017 View  |  Download
Acalabrutinib with venetoclax and obinutuzumab for treating previously untreated chronic lymphocytic leukaemia Acalabrutinib (Calquence; ACP-196) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications